Final Laboratory Report

PID :

Name	: **Mr ASR SREENIVASAN 22605**	Sex/Age	: **Male** / **90 Years**	Lab ID	: **60629625697**
Ref. By	: DR SARITA VINOD	SRF ID	:	Ref. ID	:
Corporate	: VINITA HOSPITAL (UNIT OF VIJAY GANGA SPECIALITY CARE PVT LTD)	UHID	:		

Col Dt. Time	: 27-Jun-2026 16:31	Recv Dt. Time	: 27-Jun-2026 16:31	Sample Type	: Urine
Reg Dt. Time	: 27-Jun-2026 16:31	Report Released @	: 29-Jun-2026 18:41	Report Printed	: 29-Jun-2026 18:43

TEST	RESULTS
Culture,Aerobic, Urine	
Gram Stain	Occasional pus cells and few Gram negative bacilli seen.
Colony Count	10,000 CFU/mL
	NOTE : Probably significant kindly correlate clinically.
Organism	Enterococcus species

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

MALANI.S

Verified by

Dr.M.Sowmiya
Consultant Microbiologist

MC-5972

Final Laboratory Report

PID :

Name	: **Mr ASR SREENIVASAN 22605**	Sex/Age	: **Male** / **90 Years**	Lab ID	: **60629625697**
Ref. By	: DR SARITA VINOD	SRF ID	:	Ref. ID	:
Corporate	: VINITA HOSPITAL (UNIT OF VIJAY GANGA SPECIALITY CARE PVT LTD)	UHID	:		

Col Dt. Time	: 27-Jun-2026 16:31	Recv Dt. Time	: 27-Jun-2026 16:31	Sample Type	: Urine
Reg Dt. Time	: 27-Jun-2026 16:31	Report Released @	: 29-Jun-2026 18:41	Report Printed	: 29-Jun-2026 18:43

Specimen :	**Urine**
Organism :	**Enterococcus species**

Antibiotics	**Sensitivity**
Erythromycin	RESISTANT
Penicillin G	RESISTANT
Linezolid	SUSCEPTIBLE
Doxycycline	SUSCEPTIBLE
Tetracycline	SUSCEPTIBLE
Vancomycin	SUSCEPTIBLE
Chloramphenicol	SUSCEPTIBLE
Ciprofloxacin	RESISTANT
Levofloxacin	RESISTANT
Nitrofurantoin	SUSCEPTIBLE
Norfloxacin	SUSCEPTIBLE
Ampicillin	SUSCEPTIBLE
Gentamicin High Level (Synergy)	SUSCEPTIBLE

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

MALANI.S

Verified by

Dr.M.Sowmiya
Consultant Microbiologist

MC-5972

	Final Laboratory Report			PID	:
Name	: **Mr ASR SREENIVASAN 22605**	Sex/Age	: **Male / 90 Years**	Lab ID	: **60629625697**
Ref. By	: DR SARITA VINOD	SRF ID	:	Ref. ID	:
Corporate	: VINITA HOSPITAL (UNIT OF VIJAY GANGA SPECIALITY CARE PVT LTD)			UHID	:
Col Dt. Time	: 27-Jun-2026 16:31	Recv Dt. Time	: 27-Jun-2026 16:31	Sample Type	: Urine
Reg Dt. Time	: 27-Jun-2026 16:31	Report Released @	: 29-Jun-2026 18:41	Report Printed	: 29-Jun-2026 18:43

INTERPRETATION:

1. SUSCEPTIBLE (Indicates clinically effective when used in standard therapeutic dose.)
2.INTERMEDIATE (Indicates that the drug may still be clinically effective when used with increased dose/frequency if the patient vital parameters permit. however established clinical trails are not available. It may also indicate therapeutic efficacy in physiologically concentrated sites.)3.RESISTANT (Indicates clinically ineffective when used in standard or increased therapeutic dose.)

NOTE:

Method:- DISK DIFFUSION based on CLSI guidelines.

1. It is highly recommended to use the antibiotics to which the isolate is susceptible. If 1st line antibiotic susceptible and patient already started on 2nd / Restricted antibiotics, Kindly de-escalate to any of the susceptible 1 st line antibiotic reported.
2. Extended spectrum Betalactamase(ESBL)Producer: Resistant to penicillins, cephalosporins and aztreonam.
3..Inducible Ampc: Resistance to Betalactam antibiotics and beta lactamase inhibitor Combinations like piperazilin-tazobactam,amoxicillin clavulinic acid
4 CRE (Carbapenem Resistant Enterobacteriaceae) : Intermediate or Resistant to one or more Carbapenems and resistant to 3rd generation cephalosporins .
5.MRS (Methicillin resistant Staphylococci): resistant to beta lactam agesnts with the exception of ceftaroline. 6 Methicillin susceptible Staphylococci are susceptible to
1. Beta lactum combination agents
2. Cephems
3. carbapenems

---------- End Of Report ----------

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

MALANI.S

Verified by

Dr.M.Sowmiya
Consultant Microbiologist

MC-5972